Last reviewed · How we verify
DWP16001 Amg — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
DWP16001 Amg (DWP16001 Amg) — Daewoong Pharmaceutical Co. LTD.. DWP16001 is an AMG (likely referring to a specific molecular scaffold or mechanism class) in development by Daewoong Pharmaceutical, currently in Phase 3 trials.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DWP16001 Amg TARGET | DWP16001 Amg | Daewoong Pharmaceutical Co. LTD. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DWP16001 Amg CI watch — RSS
- DWP16001 Amg CI watch — Atom
- DWP16001 Amg CI watch — JSON
- DWP16001 Amg alone — RSS
Cite this brief
Drug Landscape (2026). DWP16001 Amg — Competitive Intelligence Brief. https://druglandscape.com/ci/dwp16001-amg. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing